Dr. Robert Wong, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,037
Licensed in Texas since 2009, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license N2888 (first issued 2009; active) -
Retina Specialist (Ophthalmology) Physician
TX license N2888 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Austin Retina Associates PLLC (19 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,037
- Services billed
- 30,336
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 21,720 | 75 |
| Injection, aflibercept, 1 mg | 2,274 | 299 |
| Imaging of retina | 2,215 | 860 |
| Injection of drug into eye | 1,635 | 464 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 753 | 54 |
| Established patient office or other outpatient visit, 20-29 minutes | 656 | 398 |
| Established patient complete exam of visual system | 506 | 468 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 478 | 379 |
| Photography of the retina | 444 | 330 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 360 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Austin, TX | 72 |
| Prednisolone Acetate Other prescribers in Austin, TX | 41 |
| Ketorolac Tromethamine Other prescribers in Austin, TX | 27 |
| Timolol Maleate Other prescribers in Austin, TX | 27 |
| Bromfenac Sodium | 19 |
| Methylprednisolone Other prescribers in Austin, TX | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 50 payments worth $1,793 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $440 |
|---|---|
| Biotissue Holdings Inc. | $176 |
| Mallinckrodt Hospital Products Inc. | $160 |
| Regeneron Pharmaceuticals, Inc. | $150 |
| Genentech, Inc. | $150 |
| Alcon Vision LLC | $144 |
| Apellis Pharmaceuticals, Inc. | $142 |
| Ani Pharmaceuticals, Inc. | $108 |
| Food and Beverage | $1,793 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $1,972,053 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitre…
Boehringer Ingelheim International GmbH - A phase 2, multicenter, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema
Kyowa Kirin, Inc. - IAMD Observational Study
Genentech, Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema
Boehringer Ingelheim International GmbH - A phase 2, multicenter, randomized, double-masked, parallel group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related m…
Kyowa Kirin, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.